 |
(Photo= Yonhap news) |
[Alpha Biz= Reporter Kim Minyoung] KB Securities has raised its target price for Celltrion from 250,000 KRW to 260,000 KRW.
On the 12th, KB Securities stated, "The target price was raised to reflect the estimated earnings for the second quarter of this year, as well as the accelerating growth of ZYMFENTRA and improving cost ratios toward the end of the year."
Regarding Celltrion's second-quarter performance, KB Securities estimated, "The sales are expected to be 815.4 billion KRW, and the operating profit is expected to be 77.4 billion KRW, exceeding the consensus by 4.9% and 13.9%, respectively."
As for ZYMFENTRA, KB Securities commented, "While it is highlighted as the only infliximab SC formulation drug, the bundling effect should also be noted. Combined with the upcoming launch of the Stelara biosimilar, it can target both TNF-alpha and IL17 & IL23 mechanisms, which may induce favorable responses from both prescribers and patients."
Alphabiz Kim Minyoung (kimmy@alphabiz.co.kr)
